IMF Videos Search Content For Healthcare Professional (132) Healthcare Provider (132) Care Partner (67) Patient (67) Series - Any - ASCO/EHA (51) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (68) High-Risk Myeloma (45) High-risk Smoldering Myeloma (38) Late Relapse (4–6 Lines of Therapy) (84) MGUS (39) Newly Diagnosed (Pre-Treatment or First Treatment) (63) Smoldering Myeloma (49) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (54) Proteasome inhibitors (46) Stem cell transplant (38) Steroids (42) Supportive Care (43) Year Published 2026 (20) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma June 26, 2023 ASCO/EHA Durability of Responses with Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Myeloma June 26, 2023 ASCO/EHA Comparing Health Related Quality of Life in TCE RRMM: Ide-cel vs. Standard Regimens June 26, 2023 ASCO/EHA DREAMM-9: Belantamab mafodotin + Standard Care in Newly Diagnosed Multiple Myeloma June 22, 2023 ASCO/EHA GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266) June 20, 2023 ASCO/EHA IDE-CEL vs Standard Regimens for High-Risk Multiple Myeloma: KARMMA-3 Analysis June 19, 2023 ASCO/EHA RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Patients with Teclistamab and Talquetamab June 19, 2023 ASCO/EHA LINKER-MM1 Trial: Evaluating Linvoseltamab (REGN5458) in Patients with Relapsed or Refractory Multiple Myeloma June 14, 2023 ASCO/EHA Disparities in multiple myeloma: A global perspective on drug toxicity trends June 13, 2023 ASCO/EHA Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study June 13, 2023 ASCO/EHA Elranatamab in Combination with Daratumumab for Patients with Relapsed Refractory Multiple Myeloma: Phase 3 MagnetisMM-5 February 10, 2023 ASH Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes February 6, 2023 ASH Load More
